Medicines Adaptive Pathways to Patients: Why, When, and How to Engage?
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
22
01
2018
accepted:
01
05
2018
pubmed:
15
6
2018
medline:
15
2
2020
entrez:
15
6
2018
Statut:
ppublish
Résumé
Medicines Adaptive Pathways to Patients (MAPPs) seeks to foster access to novel beneficial treatments for the right patient groups at the earliest appropriate time in the product life-span, in a sustainable fashion. We summarize the MAPPs engagement process and critical questions to be asked at each milestone of the product life-span. These considerations are of relevance for regulatory and access pathways that strive to address the "evidence vs. access" conundrum.
Identifiants
pubmed: 29901216
doi: 10.1002/cpt.1121
pmc: PMC6585618
doi:
Substances chimiques
Drugs, Investigational
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1148-1155Informations de copyright
© 2018 The Authors Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
Clin Pharmacol Ther. 2012 Mar;91(3):426-37
pubmed: 22336591
Clin Pharmacol Ther. 2015 Mar;97(3):234-46
pubmed: 25669457
BMJ. 2016 Aug 16;354:i4437
pubmed: 27531201
Front Pharmacol. 2018 Mar 27;9:280
pubmed: 29636692
Clin Pharmacol Ther. 2014 Nov;96(5):559-71
pubmed: 25006877
Nat Rev Drug Discov. 2008 Oct;7(10):818-26
pubmed: 18787530
Front Pharmacol. 2016 Sep 28;7:305
pubmed: 27733828
Eur J Clin Pharmacol. 2005 May;61(3):231-6
pubmed: 15824914
Ther Innov Regul Sci. 2016 May;50(3):347-354
pubmed: 30227070